Nanoparticle-Based Gene Delivery for Pancreatic Applications

Nanoparticle-based gene delivery has emerged as a transformative technology for pancreatic research, offering improved stability, targeting, and efficiency. The Pancreas Nanoparticle Delivery Platform developed by Altogen Biosystems integrates a core of poly(beta-amino ester) (PBAE) with ionizable lipids (e.g., DLin-KC2-DMA) and a polyethylene glycol (PEG) surface coating. The PBAE backbone, rich in tertiary amine groups (pKa ~6.5), ensures stability at physiologic pH (pH ~7.4) and triggers protonation in acidic endosomes (pH ~5.5), inducing endosomal rupture. Ionizable lipids condense nucleic acids and assist membrane fusion, while PEGylation reduces opsonization and prolongs in vivo half-life to approximately 6 hours.

Particle sizes average 85 nm with a polydispersity index (PDI) under 0.15, optimizing enhanced permeability and retention (EPR) effects in tumor vasculature. Zeta potential measurements indicate neutrality at pH 7.4 (−2 mV), minimizing aggregation, and a shift to +15 mV in endosomes to promote cytosolic release. In vitro, these nanoparticles achieve 90% transfection efficiency of GFP plasmids in PANC-1 cells, verified by confocal microscopy showing diffuse cytosolic GFP expression versus punctate endosomal staining with generic lipofectamine.

For siRNA delivery, Altogen’s nanoparticles fully encapsulate siRNA at a N/P ratio of 8:1 (nitrogen:phosphate), yielding 75% knockdown of KRAS^G12D mRNA in MIA PaCa-2 cells at 50 nM concentration. Cytotoxicity assays (LDH release) confirm <10% cytotoxicity at optimal dosing. Furthermore, time-lapse live-cell imaging using Cy5-labeled siRNA demonstrates rapid endosomal escape within 2 hours post-transfection, suggesting efficient cargo release.

In vivo biodistribution studies employ DiR-labeled nanoparticles administered at 1 mg/kg mRNA dose, with near-infrared fluorescence imaging revealing 60% pancreatic accumulation at 8 hours and minimal hepatic retention (<10%). This preferential targeting enhances on-target delivery to orthotopic xenografts. In a study with AsPC-1 orthotopic tumors, siRNA targeting MUC1 delivered via these nanoparticles achieved an 80% reduction in MUC1 mRNA after one week, confirmed by qRT-PCR. Subsequent histological analysis showed decreased mucin deposition (Alcian Blue staining) and reduced desmoplasia (α-SMA IHC).

Altogen Labs integrates nanoparticle delivery with orthotopic xenograft services to evaluate combination therapies. For instance, co-administration of nanoparticles loaded with siRNA against HIF1α and gemcitabine resulted in a 75% reduction in orthotopic tumor volume and a 60% decrease in microvessel density (CD31 IHC). Serum amylase and lipase remain within normal limits, indicating negligible off-target pancreatic toxicity. Nanoparticle-based gene delivery thus offers a powerful, translatable platform for mechanistic studies and therapeutic development in pancreatic disease.